XpovioMM2023
Dr. Mikhael reflected on how the BOSTON and STOMP studies impacted the myeloma treatment paradigm.
Drs. Lonial, Nabhan, and Stewart discussed the plenary session at ASH, the PERSEUS trial, and treating smoldering MM.
Hamza Hashmi, MD, discusses his research at ASH 2023 and whether the results would affect the way he treats elderly patients.
Advertisement
Dr. Raje discussed the Perseus trial, in which most patients were progression-free at four years after a four-drug regimen.
The study included 84 patients with MM who had a median of four prior lines of therapy.
CAR-T therapy, while complex and expensive, has better PFS than autologous or allogenic stem cell transplantation.
Advertisement
Dr. Al-Ola Abdallah, of the University of Kansas, covers important multiple myeloma data presented at the 2023 ASH meeting.
The results suggest a possible treatment strategy of selinexor followed by immunotherapy.
The survey examined global access to 14 chemoimmunotherapy options and autologous stem cell transplant (ASCT).
Researchers point to the poor outcomes observed with existing treatments. Here's what they found.
Joshua Richter, MD, explained this finding and more results from the MyDRUG trial.
Rafael Renatino-Canevarolo, PhD, and colleagues explained just how the platform works.
Ola Landgren, MD, and colleagues presented details of the new clinical trial at the 65th ASH Annual Meeting and Exposition.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.